Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

BACKGROUND: As the selective inhibitor of BRAF kinase, vemurafenib exhibits effective antitumor activities in patients with V600 BRAF mutant melanomas. However, acquired drug resistance invariably develops after its initial treatment. METHODS: Immunohistochemical staining was performed to detect the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Jiaojiao, Fan, Wenhua, Li, Yizhuo, Tang, Ranran, Tian, Chunfang, Yang, Qian, Zhu, Tianhua, Diao, Chaoliang, Hu, Sheng, Chen, Manyu, Guo, Ping, Long, Qian, Zhang, Changlin, Qin, Ge, Yu, Wendan, Chen, Miao, Li, Liren, Qin, Lijun, Wang, Jingshu, Zhang, Xiuping, Ren, Yandong, Zhou, Penghui, Zou, Lijuan, Jiang, Kui, Guo, Wei, Deng, Wuguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360719/
https://www.ncbi.nlm.nih.gov/pubmed/30717768
http://dx.doi.org/10.1186/s13046-019-1036-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360719/
https://www.ncbi.nlm.nih.gov/pubmed/30717768
http://dx.doi.org/10.1186/s13046-019-1036-z

Ejemplares similares